TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for TNX-102 SL, a non-opioid, centrally acting ...

giving fibromyalgia sufferers a much-needed new non-opioid option. As it stands, Tonix believes 85% of fibromyalgia patients fail their first-line therapy, and 79% are on multiple therapies.

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.

fibromyalgia, and neuropathy. Additionally, this article will discuss the potential side effects of naltrexone, its dosing requirements, alternative uses, and more. Opioid antagonists are a class ...